Navigation Links
Edgemont Capital Completes Sale Of Vince & Associates Clinical Research
Date:5/15/2013

NEW YORK, May 15, 2013 /PRNewswire/ -- Edgemont Capital Partners ("Edgemont"), a specialty investment bank focused on the merger and acquisition advisory needs of healthcare companies, has acted as exclusive financial advisor to Vince and Associates Clinical Research ("Vince and Associates") in its sale to Altasciences Group.  Vince and Associates manages complex early development clinical drug trials at its state-of-the-art research facility in Overland Park, Kansas.  The transaction highlights growing demand from large pharmaceutical and biotechnology companies for conducting early development studies in patient populations. Terms of the deal were not announced.

(Logo: http://photos.prnewswire.com/prnh/20130117/NY43188LOGO )

This is the ninth transaction completed by Edgemont on behalf of clinical research site services companies and one of the largest to date, further establishing Edgemont as the leading M&A advisor to clinical research site companies. Prior transactions completed by Edgemont include the sale of Miami Research Associates, Inc. to QPS, LLC, the sale of California Clinical Trials, Inc. to Parexel Inc., and the sale of Lifetree Clinical Research, LLC to CRI Worldwide, LLC, among others.

Vince and Associates is a leader in the successful recruitment and retention of special patient populations in complex early development clinical drug trials.  The company's approach utilizes study teams led by highly experienced principal investors who are intimately involved in all aspects of the clinical trial process.  The transaction with Altasciences is a further reflection of the significant industry demand for specialized outsourcing services on the part of large pharmaceutical and biotechnology companies.

We are seeing strong acquisition interest in sophisticated site services companies like Vince and Associates that have unique and established access to highly desirable patient populations and a proven track record of research excellence," said David K. Blume , co-founder and Managing Director at Edgemont.  "Access to these populations is critical to the drug development success of pharmaceutical and biotechnology companies, and represents tremendous value."

Altasciences is owned by Kilmer Capital Partners, which also owns Algorithme Pharma, a Montreal based full service early stage clinical CRO. Both Vince and Associates Clinical Research and Algorithme Pharma operate with a common mission to provide the highest quality early stage clinical development services to an international customer base of pharmaceutical, biotechnology and generic companies with a focus on customer service.

About Edgemont Capital Partners

Edgemont Capital Partners, L.P. (www.edgemontcapital.com) is a specialty investment bank focused on the advisory needs of healthcare companies worldwide. The firm's deep healthcare industry knowledge, extensive relationship network and substantial transaction expertise allows Edgemont to address healthcare companies' strategic advisory (M&A) and financing needs with great success. Edgemont Capital Partners, L.P. provides mergers and acquisition advisory, restructuring advisory, board advisory, valuation and private placements services. Investment banking services are provided by Edgemont Capital Partners, L.P., a registered broker-dealer and member of FINRA and SIPC.

About Vince & Associates Clinical Research

Vince & Associates Clinical Research has provided clinical research services to the biopharmaceutical industry for more than a decade. Proud to be recognized in the industry as a "Center of Research Excellence", Vince & Associates has become a premier clinical research site by utilizing The Physician Research Model(R) of operation where study teams are led by highly experienced principal investigators intimately involved in all aspects of the clinical trial process.

Vince & Associates recently opened a state-of-the-art, multimillion-dollar, 90-bed clinical pharmacology unit that combines the ultimate in subject safety and luxury. This new unit has the upscale atmosphere necessary for the recruitment and retention of study volunteers in both short- and long-term clinical trials, from the safety and security of the controlled access unit to the added features of a movie theater and game rooms.


'/>"/>
SOURCE Edgemont Capital Partners, L.P.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Fewer Venture Capital Dollars Invested Into Life Sciences Companies In Q1 2013, According To The MoneyTree Report
2. New Company Abyrx, Inc. Acquires Substantially All of the Assets of Orthocon and DRG; Fully-Capitalizes to Accelerate Growth of Exciting New Biosurgical Product Portfolio
3. BioRestorative Therapies Appoints ProActive Capital Group as Capital Markets & Digital Media Advisor
4. Foundation Venture Capital Group Invests In Company Developing Implantable Meniscus for Knee Repair
5. Serina Therapeutics Announces Agreement Retaining Woodside Capital Partners as Advisor and Investment Bank
6. Creekridge Capital Announces Record Volume
7. Carolina Piedmont Capital To Exhibit At Raleigh Business Expo
8. Express Scripts Recommends Rejection of TRC Capitals "Mini-Tender" Offer
9. MedFocusCapital Partners Announces See.Hear.Live.Better! Alliance
10. Hurel Receives $9.2 Million Series A Funding From Spring Mountain Capital
11. GC-Rise Attracts Attention in Health Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , Feb. 5, 2016  Venice,s newest ... is the first of its kind in the ... tattoos through advanced laser treatment. The physician-owned and ... Suncoast by storm with its revitalizing ... and advanced multi-wavelength Astanza Trinity technology. ...
(Date:2/5/2016)... India , February 5, 2016 ... a new market research report "Fetal (Labor & Delivery) ... & Antepartum), Warmer, Incubator, Pulse Oximeter, Phototherapy/Jaundice Management Devices, ... published by MarketsandMarkets, This report studies the global market ... market is estimated at USD 6.28 Billion in 2015 ...
(Date:2/5/2016)... Feb. 5, 2016 ... the "Global Obstetrics Partnering 2010-2016: Deal ... to their offering. --> http://www.researchandmarkets.com/research/hcdvg6/global_obstetrics ... "Global Obstetrics Partnering 2010-2016: Deal trends, ... their offering. --> Research and ...
Breaking Medicine Technology:
(Date:2/5/2016)... , ... February 05, 2016 , ... ... President George H. Van Allen have signed a joint enrollment and degree completion ... seamless pathway toward associate and baccalaureate degrees at FHU|Dickson. , The agreement ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... The American ... technology, such water may be safer than regular municipal or well water. The recent ... radio host Sharon Kleyne, could go a long way toward increasing public acceptance of ...
(Date:2/5/2016)... ... February 05, 2016 , ... At its annual meeting held ... as Chairman of the National Board of Directors. Mr. McDermott succeeds former APDA Chairman, ... stated Leslie A. Chambers , APDA President and CEO. “Pat has tirelessly served ...
(Date:2/5/2016)... ... 05, 2016 , ... In sleep, when the defenses of the day are ... of patients with eating disorders is significant self-criticism, and consequently these patients experience this ... regarded as maladaptive means for coping with this unease, but also leads to a ...
(Date:2/5/2016)... , ... February 05, 2016 , ... ... Columbia University Men’s Soccer Career Development event in New York City on Thursday, ... Commisso, Chairman and CEO of Mediacom, (both alumnus of the varsity Columbia soccer ...
Breaking Medicine News(10 mins):